update Biomet, Inc. to Settle Hip Implant Suits for $56 Million

Biomet Inc. has agreed to pay at least $56 million to settle pending lawsuits over the embattled M2a Magnum hip implants, according to documents filed in the federal consolidation of cases (no. MDL 2391; U.S. District Court, Northern District of Indiana).

There are about 800 Biomet lawsuits pending in federal court, stemming from claims that the company’s M2a Magnum hip implant caused patients to suffer from serious side effects. The Biomet product joins similar products from major manufacturers such as DePuy Orthopaedics and Stryker that have been involved in major litigation and fallen under the scrutiny of the U.S. Food and Drug Administration. Johnson & Johnson and its subsidiary DePuy have agreed to a multibillion dollar DePuy ASR settlement related to claims related to a high rate of revision surgeries, according to a Nov. 20, 2013, New York Times report.

Plaintiffs in Biomet lawsuits have alleged a handful of complications, including pain, device failure and metal poisoning, according to court documents. The agreement will extend to all pending cases, and any future lawsuit filed in a federal court on or before April 15, 2014, according to a Reuters report. Plaintiffs who have received a Biomet M2a 38 or M2a Magnum hip replacement system as part of an initial hip replacement that was rectified more than 180 days after it was implanted shall receive a base award of $200,000.

The Rottenstein Law Group LLP encourages those who believe they have suffered from the Biomet’s alleged side effects to speak to a qualified lawyer immediately.

Join the Discussion

Please note: Comments are encouraged in order to permit visitors to discuss relevant topics. Comments are moderated and might be edited by RLG before being published.

Comments should not be used to ask questions of RLG’s lawyers; if you want to speak with a lawyer, please fill out this contact form or call 1 (888) 976-8529. *Your name and email address will not be published.



RLG encourages you to reproduce our original content—on your own web site; in emails to your friends and family; in blogs, posts, and tweets, etc.—but we ask that you please attribute whatever you use to us, and, whenever possible, provide a link to the page where you first found the material. That way, whoever reads your excerpt might read more informative material of interest at one of RLG's sites.
You’ve taken enough. We'll take it from here. Click here to contact us now.